Activation of a recombinant human factor VII structural analogue alters its affinity of binding to tissue factor

American Journal of Hematology

Volumn 53, Issue 2, 1996, Pages 66-71

  Sridhara, Sampath ^a   Chaing, Shu ^d   High, Katherine A ^c   Blajchman, Morris A ^a,b   Clarke, Bryan J ^a,e  

^a MCMASTER UNIVERSITY   (Canada)

^b Canadian Red Cross Society   (Canada)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Epidermal growth factor domain; Factor VII; Tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR 7; THROMBOPLASTIN;

ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN;

BINDING SITES; BINDING, COMPETITIVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMAL GROWTH FACTOR; FACTOR VII; HUMANS; MUTATION; RECOMBINANT PROTEINS; THROMBOPLASTIN;

EID: 0029959799     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199610)53:2<66::AID-AJH2>3.0.CO;2-1     Document Type: Article

References (31)

1. Hagen FS, Gray CL, O'Hara P, Grant F, Saari GC, Woodbury RG, Hart CE, Inslay M, Kisiel W, Kurachi K, Davie EW: Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci USA 83:2412-2416, 1986.
2. Bach RR: Initiation of coagulation by tissue factor. CRC Crit Rev Biochem 23:339-368, 1988.
3. Nemerson Y: Tissue factor and hemostasis. Blood 71:1-8, 1988.
4. 2+, phospholipids and tissue-faclor apoprotein to the activation of human blood coagulation factor X by activated factor VII. Biochem J 265:327-336, 1990.
5. Clarke BJ, Ofosu FA, Sridhara S, Bona RD, Rickles FR, Blajchman MA: The first epidermal growth factor domain of human coagulation factor VII is essential for binding with tissue factor. FEBS Lett 298:206-210, 1992.
6. Sridhara S, Clarke BJ, Ofosu FA, High KA, Blajchman MA: The direct binding of human factor VII in plasma to recombinant human tissue factor. Thromb Res 70:307-316, 1993.
7. Chaing S, Clarke B, Sridhara S, Chu K, Friedman P, Van Dusen W, Roberts HR, Blajchman M, Monroe DM, High K: Severe factor VII deficiency due to mutations abolishing the cleavage site for activation and altering binding to tissue factor. Blood 83:3524-3535, 1994.
8. Sridhara S, Clarke BJ, High KA, Blajchman MA: The effect of recombinant human factor VII structural analogues on the binding of biotinylated plasma factor VII to recombinant human tissue factor. Thromb Haemost 69:613, 1993.
9. Cerskus AL, Ofosu FA, Birchall KL, Clarke BJ, Modi GJ, Johnston M, Blajchman MA: The immunodepletion of factor VII from human plasma using a monoclonal antibody. Br J Haematol 61:467-475, 1985.
10. Modi GJ, Blajchman MA, Ofosu FA: The isolation of prothrombin, factor IX and factor X from human factor IX concentrate. Thromb Res 36:537-547, 1984.
11. Ofosu FA, Modi GJ, Cerskus AL, Blajchman MA, Hirsh J: Activation of factor X and prothrombin in antithrombin III depleted plasma. Thromb Res 23:331-345, 1981.
12. Mills JK, Ofosu FA, Safa TK, Siegel RS, Lessin LS: Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients. Br J Haematol 81:539-544, 1992.
13. Howard PR, Bovill EG, Pike J, Church WR, Tracy RP: Factor VII antigen levels in a healthy blood donor population. Thromb Haemost 72:21-27, 1994.
14. Seligsohn U, Osterud B, Rappaport S: Coupled amidolytic assay for factor VII: Its use with a clotting assay to determine the activity state of factor VII. Blood 52:978-988, 1978.
15. Savage D, Mattson G, Desai S, Nielander G, Morgensen S, Conklin E, eds.: Biotinylation reagents. In "Avidin-Biotin Chemistry: A Handbook." Rockford, IL: Pierce Chemical Co., 1992, pp 25-88.
16. Bylund DB, Yamamura HI: Methods for receptor binding In Yamamura HI, (eds): "Methods in Neurotransmitter Receptor Analysis." New York: Raven Press, Ltd. 1990, pp 1-35.
17. Pedersen AH, Lund-Hansen T, Bisgaard-Frantzen H, Olsen F, Petersen LC: Auto-activation of human recombinant coagulation factor VII. Biochemistry 28:9331-9336, 1989.
18. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 76:4350-4354, 1979.
19. Sakai T, Lund-Hansen T, Thim L, Kisiel W: The γ-carboxyglutamic acid domain of human factor VIIa is essential for its interaction with cell surface tissue factor. J Biol Chem 265:1890-1894, 1990.
20. Wildgoose P, Kazim AL, Kisiel W: The importance of residues 195-206 of human blood clotting factor VII in the interaction of factor VII with tissue factor. Proc Natl Acad Sci USA 87:7290-7294, 1990.
21. Wildgoose P, Berkner KL, Kisiel W: Synthesis, purification, and characterization of an Arg152Glu site-directed mutant of recombinant human blood clotting factor VII. Biochemistry 29:3413-3420, 1990.
22. Toomey JR, Smith KJ, Stafford DW: Localization of the human tissue factor recognition determinant of human factor VIIa. J Biol Chem 266:19198-19202, 1991.
23. Ruf W, Kalnik MW, Lund-Hansen T, Edgington TS: Characterization of factor VII association with tissue factor in solution. J Biol Chem 266:15719-15725, 1991.
24. O'Brien DP, Kemball-Cook G, Hutchinson AM, Martin DMA, Johnson DJD, Byfield PGH, Takamiya O, Tuddenham EGD, McVey JH: Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Demonstration of defective tissue factor binding in a variant FVII molecule (FVII-R79Q). Biochemistry 33:14162-14169, 1994.
25. Takamiya O, Kemball-Cook G, Martin DMA, Cooper DM, Von Felten A, Meili E, Hann I, Prangnell DR, Lumley H, Tuddenham EGD, McVey JH: Detection of missense mutations by single-strand conformational polymorphism (SSCP) analysis in five dysfunctional variants of coagulation factor VII. Hum Mol Genet 2:1355-1359, 1993.
26. Banner D, D'Avey A, Chene C, Winkler F, Suha A, Konigsberg W, Nemerson Y, Kirchhofer D: The crystal structure of the complex of blood coagulation factor Vila with soluble tissue factor. Nature 380:41-46, 1996.
27. Kazama Y, Foster DC, Kisiel W: Evidence that an Arg79-Gln substitution in human factor VII is not associated with a reduction in coagulation activity. Blood Coag Fibrinol 3:697-702, 1992.
28. Higashi S, Nishimura H, Aita K, Iwanaga S: Identification of regions of bovine factor VII essential for binding to tissue factor. J Biol Chem 269:18891-18898, 1994.
29. O'Brien D, Gale K, Anderson J, McVey J, Miller G, Meade T, Tuddenham E: Purification and characterization of factor VII 304-Gln: A variant molecule with reduced activity isolated from a clinically unaffected male. Blood 78:132-140, 1991.
30. Wildgoose P, Foster D, Schiodt J, Wilberg FC, Birktoft J, Petersen LC: Identification of a calcium binding site in the protease domain of human blood coagulation factor VII: Evidence for its role in factor VII-tissue factor interaction. Biochemistry 32:114-119, 1993.
31. 304→Trp). J Biol Chem 269:7355-7363, 1994.